NASDAQ: CTORCitius Oncology Inc Stock
$0.85+0.00 (+0%)
Updated May 8, 2025
CTOR Price
$0.85
Fair Value Price
-$0.05
Market Cap
$60.46M
52 Week Low
$0.55
52 Week High
$49.00
P/E
-4.45x
P/B
1.46x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$17.76M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.19
Operating Cash Flow
$345k
Beta
-0.63
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CTOR Overview
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CTOR's potential to beat the market
- CTOR doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
CTOR
RankedUnranked of 60
RankedUnranked of 60
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.25 | A | |
| $4.50 | A | |
| $7.46 | A |
Be the first to know about important CTOR news, forecast changes, insider trades & much more!
CTOR News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CTOR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CTOR ($0.85) is overvalued by 1,691.1% relative to our estimate of its Fair Value price of -$0.05 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
CTOR ($0.85) is not significantly undervalued (1,691.1%) relative to our estimate of its Fair Value price of -$0.05 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
CTOR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CTOR due diligence checks available for Premium users.
Valuation
CTOR fair value
Fair Value of CTOR stock based on Discounted Cash Flow (DCF)
Price
$0.85
Fair Value
-$0.05
Undervalued by
1,700.51%
CTOR ($0.85) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CTOR ($0.85) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CTOR is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CTOR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.45x
Industry
15.04x
Market
24.22x
CTOR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.46x
Industry
2.16x
CTOR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CTOR's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.7M
Profit Margin
0%
CTOR's Earnings (EBIT) of -$17.20M... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$90.5M
Liabilities
$49.2M
Debt to equity
1.19
CTOR's short-term liabilities ($43.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CTOR's short-term assets ($17.08M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CTOR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$0.0
Investing
$0.0
Financing
$0.0
CTOR's operating cash flow ($345.13k)... subscribe to Premium to read more.
Debt Coverage Financials
CTOR vs Pharmaceutical Stocks
Citius Oncology Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.